FTC Is Ready To Negotiate Over Amgen/Horizon Merger
Amgen asked the FTC to accept its pledge not to bundle Horizon’s Tepezza or Krystexxa, while an FTC administrative law judge urged a settlement between the agency and Amgen.
You may also be interested in...
Commission pursued merger challenge to halt pharma practices it believes can stifle competition and keep drug prices high. Other large biopharma transactions may face similar challenges as FTC pursues its new merger program.
Abbvie, Amgen, Novartis and Novo Nordisk have drugs on the list but haven’t sued yet. While they could add to the ranks of legal opposition, the Court Battle for the IRA is more about philosophy than numbers.
The FTC and DOJ revised draft merger guidelines could make it more difficult for companies to clear M&A reviews, but the agencies may have trouble winning challenges in court.